| Primary |
| Product Used For Unknown Indication |
53.1% |
| Precocious Puberty |
34.7% |
| Convulsion |
2.5% |
| Neoplasm Malignant |
1.6% |
| Asthma |
0.9% |
| Bladder Spasm |
0.9% |
| Bone Development Abnormal |
0.9% |
| Seasonal Allergy |
0.9% |
| Attention Deficit/hyperactivity Disorder |
0.6% |
| Growth Hormone Deficiency |
0.6% |
| Adrenogenital Syndrome |
0.3% |
| Astrocytoma |
0.3% |
| Bipolar I Disorder |
0.3% |
| Body Height Below Normal |
0.3% |
| Diabetes Mellitus |
0.3% |
| Drug Use For Unknown Indication |
0.3% |
| Gender Identity Disorder |
0.3% |
| Hamartoma |
0.3% |
| Hypothyroidism |
0.3% |
| Pharyngitis |
0.3% |
|
| Device Breakage |
25.9% |
| Procedural Complication |
18.5% |
| Drug Ineffective |
5.6% |
| Mood Swings |
4.9% |
| Rash |
4.9% |
| Weight Increased |
4.9% |
| Hair Growth Abnormal |
4.3% |
| Implant Site Rash |
4.3% |
| No Adverse Event |
4.3% |
| Death |
3.7% |
| Growth Accelerated |
2.5% |
| Implant Site Pain |
2.5% |
| Vomiting |
2.5% |
| Adverse Event |
1.9% |
| Hypersensitivity |
1.9% |
| Implant Site Infection |
1.9% |
| Rash Generalised |
1.9% |
| Abscess |
1.2% |
| Anxiety |
1.2% |
| Convulsion |
1.2% |
|
| Secondary |
| Precocious Puberty |
52.7% |
| Product Used For Unknown Indication |
41.8% |
| Attention Deficit/hyperactivity Disorder |
1.8% |
| Gender Identity Disorder |
1.8% |
| Thyroid Disorder |
1.8% |
|
| Procedural Complication |
15.8% |
| Weight Increased |
10.5% |
| Astrocytoma, Low Grade |
7.9% |
| Mood Swings |
7.9% |
| Death |
5.3% |
| Device Breakage |
5.3% |
| Drug Ineffective |
5.3% |
| Rash |
5.3% |
| Respiratory Disorder |
5.3% |
| Upper Respiratory Tract Infection |
5.3% |
| Deafness Neurosensory |
2.6% |
| Delayed Puberty |
2.6% |
| Growth Accelerated |
2.6% |
| Hair Growth Abnormal |
2.6% |
| Implant Site Infection |
2.6% |
| Implant Site Rash |
2.6% |
| Implant Site Scar |
2.6% |
| Infection |
2.6% |
| Laboratory Test Abnormal |
2.6% |
| Menarche |
2.6% |
|
| Concomitant |
| Growth Retardation |
100.0% |
|
|
